Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR Trial

Table 3

Change from baseline at week 12 in mean daily number of micturitions^†.

	Dry population^‡			Wet population^§
	Placebo (N = 115)	Vibegron (N = 123)	Tolterodine (N = 98)	Placebo (N = 405)	Vibegron (N = 403)	Tolterodine (N = 319)
Change from baseline at week 12
n	103	109	92	372	383	286
LS mean (SE)	‒1.0 (0.26)	‒1.8 (0.25)	‒1.3 (0.28)	‒1.7 (0.12)	‒2.1 (0.12)	‒2.0 (0.13)
95% CI	‒1.5 to ‒0.5	‒2.3 to ‒1.3	‒1.9 to ‒0.8	‒1.9 to ‒1.5	‒2.4 to ‒1.9	‒2.2 to ‒1.7
Active ‒ placebo
LSMD (SE)	‒	‒0.8 (0.36)	‒0.3 (0.38)	‒	‒0.5 (0.17)	‒0.3 (0.18)
95% CI	‒	‒1.5 to ‒0.1	‒1.1 to 0.4	‒	‒0.8 to ‒0.1	‒0.6 to 0.1

LS, least squares; LSMD, LS mean difference. ^†Analyzed using a mixed model for repeated measures with covariates for study visit, baseline number of micturitions, and treatment by study visit interaction. ^‡All randomized patients with OAB dry who took ≥1 dose of double-blind study treatment and had ≥1 evaluable change from baseline micturition measurement. ^§All randomized patients with OAB wet who took ≥1 dose of double-blind study treatment and had ≥1 evaluable change from baseline urge urinary incontinence measurement.